| EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation |
- Preliminary Discussions Underway to Establish a Joint Venture |
globenewswire.com |
2024-12-16 19:00:00 |
Czytaj oryginał (ang.) |
| EUDA Health Holdings Limited Completes Acquisition of CK Health Plus Sdn Bhd, Expanding into Direct Selling Holistic Wellness Products in Southeast Asia |
Singapore, May 08, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, proudly announces the successful completion of its acquisition of CK Health Plus Sdn Bhd (“CK Health”) today. This strategic move marks an expansion of EUDA's presence in Malaysia and underscores its commitment to revolutionizing the healthcare landscape in the region. |
globenewswire.com |
2024-05-08 12:44:00 |
Czytaj oryginał (ang.) |
| EUDA Health Expands into Direct Selling Holistic Wellness Products with Acquisition of CK Health |
SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia. |
globenewswire.com |
2024-05-06 21:00:00 |
Czytaj oryginał (ang.) |
| EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market's Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency |
Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Nasdaq on January 9, 2024 indicating that the Company had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days (the “MVLS Requirement”) as required by the Nasdaq Listing Rule 5550(b)(2). |
globenewswire.com |
2024-01-16 20:15:00 |
Czytaj oryginał (ang.) |
| EUDA Health Holdings Limited Has Received Nasdaq Notification Regarding Minimum Market Value Deficiency |
Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on January 9, 2024 indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the previous 30 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2). |
globenewswire.com |
2024-01-16 19:29:00 |
Czytaj oryginał (ang.) |
| EUDA Health Holdings Limited Enters into Letter of Intent for Proposed Merger with TheoremRx Inc. |
SINGAPORE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering enhanced outcomes through personalized healthcare, today announced that it has signed a letter of intent dated October 4, 2023, with respect to the proposed merger with TheoremRx Inc. (“TheoremRx”), a private U.S.-based company focused on the development of new treatments with safe administration, low toxicity, and a high potential for polypharmacy usage to benefit patients suffering from cancer and women's health conditions. |
globenewswire.com |
2023-10-05 13:00:00 |
Czytaj oryginał (ang.) |
| EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market's Continued Listing Requirements |
Singapore, Sept. 22, 2023 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on August 10, 2023 indicating that the Company was not in compliance with the $1.00 Minimum Bid Price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). On September 14, 2023, the Company received a written notice from Nasdaq stating that the closing bid price of the Company's common stock has been at $1.00 per share or greater for 10 consecutive business days from August 30 to September 13, 2023, and therefore the Company has regained compliance with the $1.00 Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market. |
globenewswire.com |
2023-09-22 12:00:00 |
Czytaj oryginał (ang.) |
| EUDA Health Holdings Limited Receives Nasdaq Notification Regarding Non-Compliance with Minimum Bid Price Requirement |
Singapore, Aug. 14, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). |
globenewswire.com |
2023-08-14 12:15:00 |
Czytaj oryginał (ang.) |
| EUDA Health Holdings Limited Receives Nasdaq Notification Regarding Minimum Market Value Deficiency |
Singapore, Aug. 04, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a notice (the “MVLS Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company's listed securities failed to comply with the $35 million market value of listed securities (“Market Value of Listed Securities”) requirement for continued listing on the Nasdaq Capital Market in accordance with Nasdaq Listing Rule 5550(b)(2) based upon the Company's Market Value of Listed Securities for the 30 consecutive business days prior to the date of the MVLS Notice. |
globenewswire.com |
2023-08-04 12:30:00 |
Czytaj oryginał (ang.) |